Home / Inspections / 1106822

FDA Inspection 1106822 — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. — FEI 2220525

The FDA completed an inspection of Hikma Pharmaceuticals USA Inc. on September 10, 2019 in Cherry Hill, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 10, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Cherry Hill, NJ (United States)

Facility

Other inspections at this facility

  • 1304368 (NAI Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1237333 (VAI Wed Jun 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1222115 (VAI Fri Nov 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1176451 (NAI Thu Jul 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1067645 (NAI Fri Sep 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources